Jardiance vs Metformin Side Effects: A Women's Head-to-Head Guide

What You Actually Need to Know First

These two drugs treat type 2 diabetes through completely different mechanisms, and their side-effect profiles are almost mirror images of each other. Metformin works by reducing the liver's glucose output and improving insulin sensitivity. Jardiance (empagliflozin) tells your kidneys to excrete glucose in urine rather than reabsorbing it. Because of that difference in mechanism, the things that go wrong with each drug are almost entirely distinct.

No published randomized head-to-head trial has directly compared empagliflozin and metformin side effects in women as a primary endpoint. What we have are large outcomes trials for each drug separately, plus observational and pharmacokinetic data. This article synthesizes that evidence honestly and flags where data in women specifically is thin.

One more thing before the detail: if you are currently pregnant, Jardiance is contraindicated. Stop reading the Jardiance sections and speak with your prescriber today.

The Side-Effect Profile, Side by Side

The two drugs barely overlap in what they do to your body outside of lowering blood sugar. Understanding that is the fastest way to figure out which one fits your situation.

Gastrointestinal Effects: Metformin's Biggest Drawback

Metformin's most common problem is GI upset. Studies estimate that 20-30% of people starting metformin experience nausea, diarrhea, or abdominal cramping, particularly in the first four to eight weeks. The extended-release formulation cuts that rate meaningfully, though it does not eliminate it.

Women with PCOS, who are frequently prescribed metformin off-label at doses of 1,500-2,000 mg/day, often report that GI side effects are the main reason they stop the medication. Starting at 500 mg with the evening meal and titrating by 500 mg every one to two weeks is the standard strategy to improve tolerability.

Jardiance, by contrast, has a GI side-effect rate close to placebo in clinical trials. If your GI system is already sensitive, from IBS, endometriosis-related bowel involvement, or postoperative changes, that difference matters.

Genital Yeast Infections: A Women-Specific Risk with Jardiance

Here is where Jardiance creates a problem that is specifically and disproportionately female. Because empagliflozin causes continuous glycosuria (sugar in the urine), the vulvovaginal environment becomes a feeding ground for Candida. Clinical trial data show that vulvovaginal mycotic infections occur in roughly 6-8% of women taking empagliflozin, compared with 1-3% in men. The difference is anatomical: the shorter urethra and proximity of the vaginal opening to the perineal area make women far more susceptible.

This risk is not trivial if you already deal with recurrent vulvovaginal candidiasis, whether from hormonal contraceptives, antibiotic use, or immune changes in perimenopause and beyond.

Practical steps that can reduce this risk include:

• Thorough drying of the perineal area after urination
• Loose-fitting, breathable cotton underwear
• Prompt treatment with a topical azole at the first sign of symptoms
• Discussing prophylactic fluconazole with your prescriber if you have a history of recurrent infections

Metformin carries no meaningful yeast infection risk.

Urinary Tract Infections

Both drugs have a modest association with urinary tract infections, but the mechanism and magnitude differ. Jardiance's glycosuria creates a slightly more hospitable urinary environment for bacteria. The FDA labeling for empagliflozin notes an increased risk of urinary tract infections, though the absolute increase over placebo in trials has been relatively small (around 2-3 percentage points).

Women already have a baseline UTI incidence roughly 30 times higher than men across reproductive years, so even a small added risk matters. Postmenopausal women have additional vulnerability from genitourinary syndrome of menopause (GSM), which thins urethral tissue and raises infection susceptibility. If you are postmenopausal and prone to recurrent UTIs, this is a real conversation to have with your prescriber before starting Jardiance.

Metformin is not associated with increased UTI risk.

Weight Effects

Jardiance produces a modest but consistent weight reduction, averaging 2-3 kg over 24-52 weeks in clinical trials, largely from glycosuria-related caloric loss and mild osmotic diuresis. For women managing weight alongside diabetes, especially in perimenopause when visceral fat accumulates more readily, that effect can feel like a meaningful bonus.

Metformin's effect on weight is generally neutral to mildly favorable. It does not cause hypoglycemia when used alone, and it does not produce the osmotic weight loss Jardiance does. In women with PCOS, metformin's weight effect is variable; some women see a 2-4 kg loss over six months, but many see minimal change.

Blood Pressure and Fluid Effects

Jardiance lowers systolic blood pressure by approximately 3-5 mmHg through its diuretic-like osmotic mechanism. For women entering perimenopause, when blood pressure tends to rise, that effect can be a secondary benefit.

The same mechanism can cause volume depletion, dizziness on standing (orthostatic hypotension), and dehydration, particularly in hot weather or with concurrent diuretic use. If you are on a thiazide or loop diuretic, your prescriber should review the combination carefully.

Metformin has no direct blood pressure effect.

Lactic Acidosis: Rare but Real with Metformin

Metformin carries a black-box warning for lactic acidosis, though the absolute risk is very low, estimated at roughly 3-5 cases per 100,000 patient-years in people with normal kidney function. The risk rises sharply with eGFR below 30 mL/min/1.73 m², and current FDA guidance contraindicated its use when eGFR falls below 30. Women with chronic kidney disease or acute illness causing dehydration should be monitored.

Jardiance is contraindicated when eGFR falls below 20 mL/min/1.73 m² and is not expected to provide meaningful glucose lowering at eGFR below 45, though its cardio- and renoprotective benefits may extend lower.

Diabetic Ketoacidosis: Jardiance's Rare but Serious Risk

Empagliflozin can cause euglycemic diabetic ketoacidosis (DKA), meaning DKA even when blood glucose appears normal or only mildly elevated. This makes it harder to recognize. The FDA issued a safety communication on SGLT2-inhibitor-associated DKA, and the risk is higher during prolonged fasting, surgical procedures, very low-carbohydrate diets, and acute illness. Jardiance should typically be paused at least three days before elective surgery.

Women undergoing fertility treatments that involve prolonged fasting protocols or aggressive dietary restriction should be especially aware of this.

Metformin does not cause DKA.

Cardiovascular and Long-Term Outcomes: Where Jardiance Pulls Ahead

For women with type 2 diabetes and established cardiovascular disease, Jardiance has evidence that metformin simply does not have.

The EMPA-REG OUTCOME Trial

The EMPA-REG OUTCOME trial, published in the New England England Journal of Medicine in 2015, enrolled 7,020 patients with T2D and established CVD. Empagliflozin 10 mg or 25 mg daily reduced the composite of CV death, nonfatal myocardial infarction, or nonfatal stroke by 14% versus placebo. Cardiovascular death specifically was reduced by 38%. Hospitalization for heart failure fell by 35%.

Women made up about 29% of the EMPA-REG OUTCOME population. That means the majority of the trial was male, and whether the cardiovascular benefit is identical in magnitude for women is genuinely uncertain. The trial was not powered for sex-stratified subgroup analysis. This is a real evidence gap, and you deserve to know it.

The UKPDS Legacy for Metformin

The UKPDS 34 trial, published in The Lancet in 1998, showed that metformin reduced any diabetes-related endpoint by 32% and all-cause mortality by 36% in overweight patients with newly diagnosed type 2 diabetes, compared to conventional diet therapy. This remains the foundational evidence for metformin as a first-line agent. The UKPDS was also predominantly male; women with T2D were again underrepresented.

What the UKPDS does tell us is that metformin's benefits accumulate over years. Long-term follow-up showed sustained risk reduction even after the trial ended, the so-called legacy effect.

How to Think About These Two Trials Together

These trials do not directly compete. EMPA-REG enrolled people with established CVD who were already on other diabetes medications. UKPDS enrolled people newly diagnosed with diabetes who had not yet developed complications. They answer different questions. For a 52-year-old woman newly diagnosed with type 2 diabetes and no history of heart attack or heart failure, metformin remains the standard starting point per American Diabetes Association guidelines. For a 58-year-old woman with established heart failure and type 2 diabetes, empagliflozin is now guideline-recommended.

Women-Specific Conditions: PCOS, Perimenopause, and Beyond

PCOS and Reproductive Years

Metformin has the stronger evidence base for women with PCOS. ACOG Practice Bulletin No. 194 on PCOS supports metformin use to improve menstrual regularity, reduce androgen levels, and lower the risk of gestational diabetes in women with PCOS who become pregnant. Doses of 1,500-2,000 mg/day are typical.

Jardiance has no established role in PCOS management as of this writing. Its mechanism does not address the hyperandrogenism or ovulatory dysfunction that drives PCOS, and there are no adequately powered trials in this population.

Perimenopause and Menopause

Estrogen decline during perimenopause increases insulin resistance, which is one reason type 2 diabetes risk rises significantly in the decade around the final menstrual period. Both drugs address insulin resistance or glucose excretion, but they do so differently in this context.

A life-stage framework for choosing between these drugs in perimenopause:

| Life Stage | Primary Concern | Preferred Starting Point | Notes | |---|---|---|---| | Early perimenopause, no CVD | Rising insulin resistance, weight gain | Metformin | Established safety, PCOS crossover benefit | | Late perimenopause or postmenopause, established CVD or HF | CV risk reduction | Jardiance | EMPA-REG benefit; watch UTI risk with GSM | | Postmenopause, recurrent UTI or yeast infections | Infection susceptibility | Metformin preferred | Jardiance's glycosuria adds risk | | Any stage, planning pregnancy | Pregnancy safety | Metformin only | Jardiance contraindicated |

Postmenopausal women considering Jardiance should discuss the intersection of genitourinary syndrome of menopause and SGLT2-inhibitor-related infection risk explicitly with their prescriber. Local vaginal estrogen, which is safe and not systemically absorbed at standard doses, may reduce UTI and yeast risk if Jardiance is the right metabolic choice.

Female-Pattern Metabolic Disease

Women with type 2 diabetes are at higher relative cardiovascular risk than men with the same diagnosis. A meta-analysis in the Journal of the American Medical Association found that women with type 2 diabetes have a 44% higher excess relative risk of coronary artery disease than men with the same condition. That sex disparity makes the CVD-protective benefits of Jardiance potentially even more relevant for women with established disease, though the direct evidence from EMPA-REG in women alone remains limited.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, trying to conceive, or breastfeeding.

Metformin in Pregnancy and Lactation

Metformin is not FDA-approved for use in pregnancy but is widely used off-label for gestational diabetes and PCOS-related pregnancy complications. A Cochrane review found metformin to be an effective and generally safe option for gestational diabetes, though long-term offspring outcomes require more study. Metformin crosses the placenta, reaching fetal concentrations similar to maternal levels. Current evidence does not show increased rates of fetal malformation.

ACOG Practice Bulletin No. 201 on gestational diabetes acknowledges metformin as an acceptable pharmacologic option when insulin is declined or unavailable, though it states that insulin remains the preferred agent.

Metformin is present in breast milk at low concentrations. Infant exposure is estimated at less than 0.5% of the maternal weight-adjusted dose. Major breastfeeding guidelines consider it compatible with lactation, though formal studies in this area are limited.

If you are trying to conceive and have PCOS, discuss with your prescriber whether to continue metformin through the first trimester; the evidence for reducing early pregnancy loss in PCOS with metformin is mixed.

Jardiance in Pregnancy and Lactation

Jardiance is contraindicated in pregnancy. Animal studies showed adverse fetal renal effects with SGLT2 inhibitors during organogenesis and in the second and third trimesters. The FDA label for empagliflozin states that the drug should be discontinued as soon as pregnancy is detected.

There are no adequate human data on Jardiance use in pregnancy. The mechanism, which promotes glycosuria and volume shifts, poses theoretical risks to fetal renal development.

Jardiance is not recommended during breastfeeding. There are no human lactation studies. Given the drug's renal mechanism, the lack of safety data, and the availability of alternatives, it should be avoided.

Contraception note: Women of reproductive age who are prescribed Jardiance should use reliable contraception. If you are planning a pregnancy, transition off Jardiance before trying to conceive, ideally with a clinical plan for alternative glucose management in place.

Who This Is Right For and Who It Is Not

Metformin Is Likely the Better Fit If You:

• Are newly diagnosed with type 2 diabetes and have no established cardiovascular disease
• Have PCOS, whether or not you have a formal diabetes diagnosis
• Are pregnant, planning pregnancy, or breastfeeding
• Have a history of recurrent vulvovaginal yeast infections
• Cannot afford a brand-name medication (generic metformin costs under $10/month at most pharmacies)
• Have GI sensitivity and are willing to use the extended-release formulation with food

Jardiance Is Likely the Better Fit If You:

• Have type 2 diabetes and established cardiovascular disease, heart failure with reduced or preserved ejection fraction, or chronic kidney disease with proteinuria
• Have already tried metformin and cannot tolerate its GI effects
• Are postmenopausal and your prescriber has assessed that your UTI/yeast risk is manageable
• Need modest blood pressure and weight reduction alongside glucose control
• Are not pregnant and are using reliable contraception

Neither Drug Is a Good Fit If You:

• Have an eGFR below 30 (metformin contraindicated) or below 20 (Jardiance provides minimal benefit, also avoid)
• Are pregnant (Jardiance absolutely contraindicated; metformin only with prescriber guidance)
• Have a history of recurrent euglycemic DKA or prolonged fasting states (Jardiance risk)

Practical Side-Effect Management by Drug

Managing Metformin Side Effects

Starting low and going slow is the most evidence-supported strategy. Beginning at 500 mg once daily with the largest meal and increasing by 500 mg every one to two weeks reduces GI intolerance significantly. Switching to extended-release metformin (metformin XR or Glumetza) further reduces diarrhea and nausea without sacrificing efficacy.

Vitamin B12 depletion is a real long-term concern with metformin. Studies show that metformin reduces B12 absorption in roughly 10-30% of long-term users, and B12 deficiency can cause peripheral neuropathy, which may be mistaken for diabetic neuropathy. Annual B12 monitoring is reasonable after three or more years of metformin use.

Managing Jardiance Side Effects

Genital hygiene matters more on Jardiance than on most other medications. Wiping front to back, drying the perineal area thoroughly, and wearing breathable fabrics are not overly complicated steps but do meaningfully reduce Candida risk.

Stay well-hydrated. Jardiance's osmotic mechanism means you are losing fluid through your urine. Women who are already on diuretics need a prescriber review of their hydration status before starting.

Hold Jardiance three days before any elective surgical procedure to reduce euglycemic DKA risk. The FDA's guidance on this is explicit, and surgical teams may not automatically ask about SGLT2 inhibitors by name.

The Evidence Gap: What We Still Do Not Know About Women

Both EMPA-REG OUTCOME and UKPDS 34 enrolled majority-male populations. Women made up approximately 29% of EMPA-REG and roughly 40% of the overweight metformin group in UKPDS 34. Neither trial was powered to confirm that the primary outcomes held equally across sexes.

Sex-specific pharmacokinetic data show that women tend to have higher plasma concentrations of empagliflozin at equivalent doses due to lower body weight and renal clearance differences, though the clinical significance of this has not been fully characterized. Metformin's distribution and clearance are also modestly different in women, though dose adjustments based on sex are not currently standard practice.

The American Diabetes Association's Standards of Care do not stratify metformin or SGLT2 inhibitor recommendations by sex. That is not because the evidence is identical across sexes; it is because sex-stratified data simply have not been collected at sufficient scale.

Women deserve to know this, not to avoid these medications, but to understand that some of the numbers cited in prescribing conversations come from populations that do not look like them.